3rd Quarter - Report

BECTON, DICKINSON AND COMPANY for BECTON DICKINSON AND COMPANY

Firm
Client
Income
—
Expenses
$110,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S.959, Pharmaceutical Compounding Quality and Accountability Act, Issues related to drug compounding FDA regulation of diagnostic tests

LobbyistCovered position, as disclosed
JENNIFER M LURAY —
DANNY LY —
ELIZABETH WOODY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 959 (113th)

Medicare/Medicaid MMM

Reimbursement for diagnostic tests

LobbyistCovered position, as disclosed
JENNIFER M LURAY —
DANNY LY —
ELIZABETH WOODY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

H.R.523, Protect Medical Innovation Act of 2013 Corporate tax issues

LobbyistCovered position, as disclosed
JENNIFER M LURAY —
DANNY LY —
ELIZABETH WOODY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 523 (113th)

Budget/Appropriations BUD

NIH Funding FDA Funding PEPFAR Funding

LobbyistCovered position, as disclosed
JENNIFER M LURAY —
DANNY LY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.